Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (F
Post# of 135
(Total Views: 210)
Posted On: 04/13/2022 3:46:56 PM
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable
- Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1
- SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant
- Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far, the company has explored MDMA, LSD, DMT, mescaline, 2C-B, and psilocybin mushrooms (https://nnw.fm/rVscs).
These efforts have offered more effective alternatives to individuals dealing with treatment-resistant depression, anxiety, or post-traumatic stress disorder (“PTSD”). As it currently stands, over 63% of Americans who have used prescription medications to treat depression, anxiety, or PTSD, have reported that while the medication helped, they still underwent residual feelings of their conditions.
In addition, 83% of those who have experienced these conditions before have noted that they are open to exploring alternative treatments that are more effective than prescription medications.
In what marked a significant move for the company, Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings and the largest ketamine therapy provider in the United States, announced the expansion of its treatment options to include SPRAVATO(R) nasal spray beginning April 1 (https://nnw.fm/JjBzj).
SPRAVATO is the first FDA-approved ekestamine nasal spray for adults, made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions.
SPRAVATO received FDA approval for the treatment of TRD back in 2019 following an efficacy evaluation in three short-term (four-week) clinical tests, along with one longer-term maintenance-of-effect trial. The nasal spray would be used in conjunction with an oral antidepressant and would only be available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (“REMS”) (https://nnw.fm/QbVv0).
While making the announcement, Kevin Nicholson, the Chief Executive Officer (“CEO”) of KWC and the Chief Operating Officer (“COO”) of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider.
“Ketamine Wellness Centers strives to be our patients’ strongest advocate by providing effective and affordable mental health treatment, and SPRAVATO is the next step in maintaining that standard,” Mr. Nicholson noted.
Patients who might be interested in this treatment option will undergo KWC’s thorough intake and screening process to ensure they are suitable candidates and would gain the most benefit from the treatment. In addition, KWC’s clinical protocols provide that SPRAVATO treatments are administered in precisely the proper care and patient safety settings.
“Our team rigorously studied SPRAVATO’s clinical efficacy before offering the treatment to our wider patient community and expanding our care options,” noted Mr. Nicholson.
“We are confident that adding this treatment to our mental wellness centers will greatly benefit our patients,” he added.
Since Delic completed the acquisition of KWC in November 2021, it has been on an aggressive expansion plan, growing the number of locations to 13, up from 10, with plans to open more locations in the coming months. So far, these facilities serve communities across nine states in the United States and have provided over 70,000 treatments to clinically eligible patients, ranging from young adults to seniors (https://nnw.fm/v4ddU).
The addition of SPRAVATO to KWC’s list of offerings guarantees more options for its patients. In addition, it allows both KWC and Delic to provide effective and affordable mental health treatment to patients across the country.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://nnw.fm/DELCF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1
- SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant
- Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far, the company has explored MDMA, LSD, DMT, mescaline, 2C-B, and psilocybin mushrooms (https://nnw.fm/rVscs).
These efforts have offered more effective alternatives to individuals dealing with treatment-resistant depression, anxiety, or post-traumatic stress disorder (“PTSD”). As it currently stands, over 63% of Americans who have used prescription medications to treat depression, anxiety, or PTSD, have reported that while the medication helped, they still underwent residual feelings of their conditions.
In addition, 83% of those who have experienced these conditions before have noted that they are open to exploring alternative treatments that are more effective than prescription medications.
In what marked a significant move for the company, Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings and the largest ketamine therapy provider in the United States, announced the expansion of its treatment options to include SPRAVATO(R) nasal spray beginning April 1 (https://nnw.fm/JjBzj).
SPRAVATO is the first FDA-approved ekestamine nasal spray for adults, made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions.
SPRAVATO received FDA approval for the treatment of TRD back in 2019 following an efficacy evaluation in three short-term (four-week) clinical tests, along with one longer-term maintenance-of-effect trial. The nasal spray would be used in conjunction with an oral antidepressant and would only be available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (“REMS”) (https://nnw.fm/QbVv0).
While making the announcement, Kevin Nicholson, the Chief Executive Officer (“CEO”) of KWC and the Chief Operating Officer (“COO”) of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider.
“Ketamine Wellness Centers strives to be our patients’ strongest advocate by providing effective and affordable mental health treatment, and SPRAVATO is the next step in maintaining that standard,” Mr. Nicholson noted.
Patients who might be interested in this treatment option will undergo KWC’s thorough intake and screening process to ensure they are suitable candidates and would gain the most benefit from the treatment. In addition, KWC’s clinical protocols provide that SPRAVATO treatments are administered in precisely the proper care and patient safety settings.
“Our team rigorously studied SPRAVATO’s clinical efficacy before offering the treatment to our wider patient community and expanding our care options,” noted Mr. Nicholson.
“We are confident that adding this treatment to our mental wellness centers will greatly benefit our patients,” he added.
Since Delic completed the acquisition of KWC in November 2021, it has been on an aggressive expansion plan, growing the number of locations to 13, up from 10, with plans to open more locations in the coming months. So far, these facilities serve communities across nine states in the United States and have provided over 70,000 treatments to clinically eligible patients, ranging from young adults to seniors (https://nnw.fm/v4ddU).
The addition of SPRAVATO to KWC’s list of offerings guarantees more options for its patients. In addition, it allows both KWC and Delic to provide effective and affordable mental health treatment to patients across the country.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://nnw.fm/DELCF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)